Factor IX Complex (Human)
- Atc Codes:B02BD04#B02BD01
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Benefix; Belgium: Benefix, Mononine, Nonafact, Octanine; Bulgaria: Immunine, Octanine F; Cyprus: Benefix; Czech Republic: Immunine, Mononine, Nonafact, Octanine F; Denmark: Benefix; Estonia: Benefix, Immunine, Nonafact; Finland: Benefix, Nonafact, Octanine; France: Benefix; Germany: BeneFIX, Immunine, Mononine, Nonafact; Greece: Benefix, Mononine; Hungary: Humafactor-9, Mononine, Nonafact, Octanine F; Ireland: Benefix, Immunine, Nanotiv, Nonafact; Italy: Benefix; Latvia: Immunine, Nonafact; Lithuania: BeneFIX, Immunine, Nonafact; Malta: Aimafix, Replenine VF; Netherlands: Alphanine, Betafact, Mononine, Nonafact; Poland: Immunine, Nonafact, Octanine F; Portugal: Aimafix, Betafact, Immunine, Mononine, Nanotiv, Nonafact, Octaninef; Romania: Immunine, Nonafact, Octanine F; Slovakia: BeneFIX, Immunine, Mononine, Nonafact, Octanine F; Slovenia: Immunine, Mononine, Octanine F; Spain: Factor IX, Immunine, Mononine, Nanotiv; Sweden: BeneFIX, Immunine, Mononine, Nanotiv, Nonafact; UK: AlphaNine, Mononine, Replenine VF.
North America
Canada: Benefix, Immunine, Mononine; USA: Bebulin VH, Profilnine SD.
Latin America
Argentina: Aimafix D.I., Benefix, Immunine, Octanine F; Mexico: Octanine F, Replenine VF.
Drug combinations
Factor IX, Factor II, Factor VII, and Factor X
Factor IX, Factor II, Factor VII, and Factor X, and Protein C Concentrate (Human)
Chemistry
Pharmacologic Category
Antihemorrhagic Agents; Hemostatics. Antihemophilic Agent. Blood Product Derivative. (ATC-Code: B02BD04; B02BD01).
Mechanism of action
Replaces deficient clotting factor including factor X. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII: C, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot.
Therapeutic use
Control of bleeding in patients with factor, IX deficiency (hemophilia B or Christmas disease).
Pregnancy and lactiation implications
Unlabeled use
Emergency correction of the coagulopathy of warfarin excess in critical situations.
Contraindications
Liver disease with signs of intravascular coagulation or fibrinolysis. Not for use in factor VII deficiencies, or in patients undergoing elective surgery.
Warnings and precautions
Thrombotic events rarely occur (more likely to occur during postoperative period or in patients with risk factors). Unstable vital signs (respiratory distress or changes in blood pressure or pulse rate) might occur. Use with extreme caution in hepatic impairment. Product of human plasma (may potentially contain infectious agents which could transmit disease).